Haemonetics has outperformed analyst expectations in seven of its last eight quarters, delivering an average earnings surprise of 8.4%. Since fiscal 2023, the company has consistently reported revenue growth above consensus forecasts, with organic sales rising 5.2% year-over-year in its most recent quarterly release. This pattern underscores management’s ability to control costs and drive top-line expansion across its bleeding management and interventional technologies segments.

Analyst models project a modest uptick in adjusted EPS to $1.08 for Haemonetics’ upcoming quarter, supported by ongoing productivity initiatives that have trimmed manufacturing expenses by 120 basis points over the past year. Concurrently, durable demand in structural heart procedures—where Haemonetics holds a 35% share of the large-bore vascular closure market—provides pricing leverage. These operational efficiencies combined with stable end-market growth form the core rationale for expecting a second consecutive upside surprise.

Haemonetics announced the €100 million upfront acquisition of Ireland-based Vivasure Medical, plus up to €85 million in milestone payments tied to regulatory approvals and sales targets. The deal brings the PerQseal Elite bioabsorbable closure system into Haemonetics’ interventional lineup, addressing large-bore access sites up to 26F. Vivasure’s CE Mark approvals for both arterial and venous applications and its pending FDA Premarket Approval submission in 2025 bolster Haemonetics’ entry into high-growth structural heart and endovascular procedure categories.

As of September 27, 2025, Haemonetics held $296.4 million in cash, enabling the Vivasure acquisition to be fully funded from existing resources. Management has signaled that fiscal Q3 results, due February 5, will include updated capital allocation plans and integration milestones. Investors will watch for any adjustments to full-year guidance, particularly regarding incremental R&D investment targeting next-generation closure technologies and anticipated synergies from the Vivasure transaction.